Symbols / ALT Stock $3.09 +1.64% Altimmune, Inc.
ALT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Ratings
Current target
$3.09
Low
$2.50
High
$28.00
Mean
$18.15
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2026-03-06 | main | B. Riley Securities | Buy → Buy | $13 |
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $14 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-08-13 | main | UBS | Buy → Buy | $24 |
| 2025-08-13 | main | B. Riley Securities | Buy → Buy | $18 |
| 2025-07-10 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-02 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $25 |
| 2025-03-14 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $25 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-28 | init | William Blair | — → Market Perform | — |
| 2025-02-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-08 | init | Stifel | — → Buy | $18 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
News
RSS: Latest ALT news- Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Yahoo Finance Sun, 26 Apr 2026 07
- Altimmune (NASDAQ: ALT) shareholders approve doubling share authorization - Stock Titan hu, 16 Apr 2026 07
- LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN Fri, 01 May 2026 18
- $ALT stock is down 13% today. Here's what we see in our data. - Quiver Quantitative hu, 23 Apr 2026 07
- Altimmune seeks Phase 3 liver trial funds in stock sale - Stock Titan Wed, 22 Apr 2026 07
- ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance hu, 26 Mar 2026 07
- ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN Sat, 25 Apr 2026 22
- May 13: Altimmune to post Q1 results, give business update - Stock Titan Wed, 06 May 2026 11
- ALT Stock: What Pemvidutide Means for MASH, AUD and ALD - Yahoo Finance hu, 23 Apr 2026 07
- CBOJ | Calamos Bitcoin Structured Alt Stock Data, Price & News - Quiver Quantitative hu, 16 Apr 2026 04
- ALT SEC Filings - Altimmune 10-K, 10-Q, 8-K Forms - Stock Titan ue, 05 May 2026 09
- ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative hu, 05 Mar 2026 08
- Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Yahoo Finance ue, 17 Feb 2026 08
- Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan Mon, 27 Apr 2026 07
- ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Yahoo Finance ue, 06 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.04
+105.00%
|
0.02
-95.31%
|
0.43
+726.47%
|
-0.07
|
| Operating Revenue |
|
0.04
+105.00%
|
0.02
-95.31%
|
0.43
+726.47%
|
-0.07
|
| Operating Expense |
|
94.53
-8.39%
|
103.19
+22.94%
|
83.94
-4.26%
|
87.67
|
| Research And Development |
|
66.43
-19.21%
|
82.23
+24.97%
|
65.80
-6.72%
|
70.54
|
| Selling General And Administration |
|
28.10
+34.02%
|
20.97
+15.60%
|
18.14
+5.85%
|
17.13
|
| General And Administrative Expense |
|
28.10
+34.02%
|
20.97
+15.60%
|
18.14
+5.85%
|
17.13
|
| Other Gand A |
|
28.10
+34.02%
|
20.97
+15.60%
|
18.14
+5.85%
|
17.13
|
| Total Expenses |
|
94.53
-8.39%
|
103.19
+22.94%
|
83.94
-4.26%
|
87.67
|
| Operating Income |
|
-94.49
+8.42%
|
-103.17
-23.54%
|
-83.51
+4.82%
|
-87.74
|
| Total Operating Income As Reported |
|
-94.49
+8.42%
|
-103.17
-7.55%
|
-95.93
-9.33%
|
-87.74
|
| EBITDA |
|
-87.03
+8.21%
|
-94.81
-7.82%
|
-87.94
-4.18%
|
-84.41
|
| Normalized EBITDA |
|
-87.03
+8.21%
|
-94.81
-25.55%
|
-75.52
+10.54%
|
-84.41
|
| Reconciled Depreciation |
|
0.11
-52.94%
|
0.24
-50.10%
|
0.48
-3.25%
|
0.49
|
| EBIT |
|
-87.14
+8.32%
|
-95.05
-7.51%
|
-88.41
-4.13%
|
-84.90
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-12.42
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-12.42
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-12.42
|
0.00
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
12.42
|
0.00
|
| Net Income |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Pretax Income |
|
-88.77
+6.61%
|
-95.06
-7.48%
|
-88.45
-4.17%
|
-84.91
|
| Net Non Operating Interest Income Expense |
|
5.91
-26.78%
|
8.06
+10.24%
|
7.32
+155.63%
|
2.86
|
| Interest Expense Non Operating |
|
1.64
+18077.78%
|
0.01
-74.29%
|
0.04
+337.50%
|
0.01
|
| Net Interest Income |
|
5.91
-26.78%
|
8.06
+10.24%
|
7.32
+155.63%
|
2.86
|
| Interest Expense |
|
1.64
+18077.78%
|
0.01
-74.29%
|
0.04
+337.50%
|
0.01
|
| Interest Income Non Operating |
|
7.54
-6.60%
|
8.07
+9.84%
|
7.35
+156.13%
|
2.87
|
| Interest Income |
|
7.54
-6.60%
|
8.07
+9.84%
|
7.35
+156.13%
|
2.87
|
| Other Income Expense |
|
-0.19
-495.83%
|
0.05
+100.39%
|
-12.25
-38190.63%
|
-0.03
|
| Other Non Operating Income Expenses |
|
-0.19
-495.83%
|
0.05
-71.08%
|
0.17
+618.75%
|
-0.03
|
| Tax Provision |
|
-0.68
|
0.00
|
0.00
+100.00%
|
-0.20
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Net Income From Continuing Operation Net Minority Interest |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Net Income From Continuing And Discontinued Operation |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Net Income Continuous Operations |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Normalized Income |
|
-88.09
+7.33%
|
-95.06
-25.03%
|
-76.03
+10.25%
|
-84.71
|
| Net Income Common Stockholders |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Diluted EPS |
|
-1.00
+25.37%
|
-1.34
+19.28%
|
-1.66
+8.29%
|
-1.81
|
| Basic EPS |
|
-1.00
+25.37%
|
-1.34
+19.28%
|
-1.66
+8.29%
|
-1.81
|
| Basic Average Shares |
|
88.10
+24.08%
|
71.00
+33.35%
|
53.25
+13.47%
|
46.93
|
| Diluted Average Shares |
|
88.10
+24.08%
|
71.00
+33.35%
|
53.25
+13.47%
|
46.93
|
| Diluted NI Availto Com Stockholders |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
210.64
|
| Current Assets |
|
209.63
|
| Cash Cash Equivalents And Short Term Investments |
|
197.81
|
| Cash And Cash Equivalents |
|
135.12
|
| Other Short Term Investments |
|
62.70
|
| Receivables |
|
4.85
|
| Accounts Receivable |
|
1.11
|
| Taxes Receivable |
|
3.74
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
0.04
|
| Other Current Assets |
|
6.92
|
| Total Non Current Assets |
|
1.01
|
| Net PPE |
|
0.65
|
| Gross PPE |
|
2.63
|
| Accumulated Depreciation |
|
-1.98
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.54
|
| Other Properties |
|
0.34
|
| Leases |
|
1.75
|
| Goodwill And Other Intangible Assets |
|
0.00
|
| Other Intangible Assets |
|
—
|
| Other Non Current Assets |
|
0.36
|
| Total Liabilities Net Minority Interest |
|
16.54
|
| Current Liabilities |
|
12.14
|
| Payables And Accrued Expenses |
|
11.65
|
| Payables |
|
2.07
|
| Accounts Payable |
|
2.07
|
| Current Accrued Expenses |
|
9.58
|
| Total Tax Payable |
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.50
|
| Current Capital Lease Obligation |
|
0.50
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
4.40
|
| Long Term Debt And Capital Lease Obligation |
|
0.17
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.17
|
| Non Current Deferred Liabilities |
|
—
|
| Non Current Deferred Revenue |
|
—
|
| Other Non Current Liabilities |
|
4.22
|
| Stockholders Equity |
|
194.10
|
| Common Stock Equity |
|
194.10
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Share Issued |
|
70.68
|
| Ordinary Shares Number |
|
70.68
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
665.43
|
| Retained Earnings |
|
-466.33
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.00
|
| Other Equity Adjustments |
|
-5.00
|
| Total Equity Gross Minority Interest |
|
194.10
|
| Total Capitalization |
|
194.10
|
| Working Capital |
|
197.48
|
| Invested Capital |
|
194.10
|
| Total Debt |
|
0.67
|
| Capital Lease Obligations |
|
0.67
|
| Net Tangible Assets |
|
194.10
|
| Tangible Book Value |
|
194.10
|
| Interest Payable |
|
0.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-67.53
+15.42%
|
-79.85
-5.33%
|
-75.81
-21.13%
|
-62.59
|
| Cash Flow From Continuing Operating Activities |
|
-67.53
+15.42%
|
-79.85
-5.33%
|
-75.81
-21.13%
|
-62.59
|
| Net Income From Continuing Operations |
|
-88.09
+7.33%
|
-95.06
-7.48%
|
-88.45
-4.41%
|
-84.71
|
| Depreciation Amortization Depletion |
|
0.11
-52.94%
|
0.24
-50.10%
|
0.48
-3.25%
|
0.49
|
| Depreciation |
|
0.11
-52.94%
|
0.24
-50.10%
|
0.48
-3.25%
|
0.49
|
| Depreciation And Amortization |
|
0.11
-52.94%
|
0.24
-50.10%
|
0.48
-3.25%
|
0.49
|
| Other Non Cash Items |
|
0.36
|
—
|
—
|
0.09
|
| Stock Based Compensation |
|
16.08
+11.69%
|
14.39
+35.27%
|
10.64
+31.34%
|
8.10
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
12.42
|
0.00
|
| Deferred Tax |
|
-0.68
|
0.00
|
—
|
—
|
| Deferred Income Tax |
|
-0.68
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
0.16
+433.33%
|
-0.05
+68.83%
|
-0.15
-552.94%
|
0.03
|
| Net Foreign Currency Exchange Gain Loss |
|
0.16
+433.33%
|
-0.05
+68.83%
|
-0.15
-552.94%
|
0.03
|
| Change In Working Capital |
|
6.75
+50.78%
|
4.48
+154.12%
|
-8.27
-158.64%
|
14.11
|
| Change In Receivables |
|
2.06
+18.72%
|
1.74
+175.09%
|
-2.31
-170.10%
|
3.30
|
| Changes In Account Receivables |
|
-0.68
-219.05%
|
0.57
+160.45%
|
-0.94
-466.41%
|
0.26
|
| Change In Prepaid Assets |
|
-0.20
-104.33%
|
4.71
+450.41%
|
-1.34
-150.75%
|
2.65
|
| Change In Payables And Accrued Expense |
|
4.89
+348.35%
|
-1.97
+57.31%
|
-4.62
-156.56%
|
8.16
|
| Change In Accrued Expense |
|
2.39
+2233.04%
|
-0.11
+94.05%
|
-1.88
-134.92%
|
5.39
|
| Change In Payable |
|
2.51
+234.80%
|
-1.86
+32.00%
|
-2.73
-198.70%
|
2.77
|
| Change In Account Payable |
|
2.51
+234.80%
|
-1.86
+32.00%
|
-2.73
-198.70%
|
2.77
|
| Investing Cash Flow |
|
-132.47
-366.68%
|
-28.39
-306.71%
|
13.73
+118.71%
|
-73.40
|
| Cash Flow From Continuing Investing Activities |
|
-132.47
-366.68%
|
-28.39
-306.71%
|
13.73
+118.71%
|
-73.40
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
+100.00%
|
-0.05
+62.70%
|
-0.13
|
| Purchase Of PPE |
|
-0.01
|
0.00
+100.00%
|
-0.05
+62.70%
|
-0.13
|
| Capital Expenditure |
|
-0.01
|
—
|
-0.05
+62.70%
|
-0.13
|
| Net Investment Purchase And Sale |
|
-132.46
-366.65%
|
-28.39
-306.01%
|
13.78
+118.81%
|
-73.27
|
| Purchase Of Investment |
|
-285.45
-146.65%
|
-115.73
-30.58%
|
-88.63
-20.96%
|
-73.27
|
| Sale Of Investment |
|
152.99
+75.15%
|
87.34
-14.71%
|
102.41
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
206.84
+1959.36%
|
10.04
-88.34%
|
86.11
+51.64%
|
56.78
|
| Cash Flow From Continuing Financing Activities |
|
206.84
+1959.36%
|
10.04
-88.34%
|
86.11
+51.64%
|
56.78
|
| Net Issuance Payments Of Debt |
|
35.00
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
35.00
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
35.00
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
35.00
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
173.73
+1638.37%
|
9.99
-88.46%
|
86.60
+53.69%
|
56.35
|
| Proceeds From Stock Option Exercised |
|
0.33
-63.11%
|
0.90
+174.39%
|
0.33
-65.47%
|
0.95
|
| Net Other Financing Charges |
|
-2.22
-161.53%
|
-0.85
-3.16%
|
-0.82
-59.69%
|
-0.52
|
| Changes In Cash |
|
6.83
+106.96%
|
-98.19
-508.67%
|
24.03
+130.34%
|
-79.20
|
| Beginning Cash Position |
|
36.97
-72.65%
|
135.16
+21.62%
|
111.13
-41.61%
|
190.34
|
| End Cash Position |
|
43.80
+18.49%
|
36.97
-72.65%
|
135.16
+21.62%
|
111.13
|
| Free Cash Flow |
|
-67.55
+15.41%
|
-79.85
-5.26%
|
-75.86
-20.96%
|
-62.71
|
| Interest Paid Supplemental Data |
|
0.97
|
0.00
|
—
|
—
|
| Amortization Of Securities |
|
-2.22
+42.23%
|
-3.85
-55.81%
|
-2.47
-254.01%
|
-0.70
|
| Common Stock Issuance |
|
173.73
+1638.37%
|
9.99
-88.46%
|
86.60
+53.69%
|
56.35
|
| Issuance Of Capital Stock |
|
173.73
+1638.37%
|
9.99
-88.46%
|
86.60
+53.69%
|
56.35
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 42026-05-01 View
- 8-K2026-04-24 View
- 8-K2026-04-16 View
- 42026-04-06 View
- 42026-04-01 View
- 42026-04-01 View
- 42026-03-09 View
- 42026-03-09 View
- 10-K2026-03-06 View
- 8-K2026-03-05 View
- 42026-02-27 View
- 42026-02-27 View
- 42026-02-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|